You do not currently have access to this content.
Cancer Res (2025) 85 (8_Supplement_2): ND11.
Abstract. TNG462 is a clinical-stage, MTA-cooperative PRMT5 inhibitor currently being evaluated in an ongoing phase I/II clinical trial for solid tumors with MTAP loss. Approximately 10-15% of all ...
University of Minnesota, Minneapolis, MN.
The combination of anti-TROP2 ADCs with PD-(L)1 inhibitors represents a promising therapeutic strategy, merging targeted therapy with immunotherapy to improve treatment outcomes. Clinical trials are ...
The Chimeric Antigen Receptor (CAR) T cell therapy has emerged as a ground-breaking immunotherapeutic approach in cancer treatment and demonstrated encouraging clinical results in autoimmune disease ...
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio ® (avelumab), a ...
1Department of Oncology, Mayo Clinic, Rochester, Minnesota.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results